82 related articles for article (PubMed ID: 24119435)
1. Factors associated with virological failure in a cohort of combination antiretroviral therapy-treated patients managed at a tertiary referral centre.
Fong R; Cheng AC; Vujovic O; Hoy JF
Sex Health; 2013 Nov; 10(5):442-7. PubMed ID: 24119435
[TBL] [Abstract][Full Text] [Related]
2. Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection.
Farías AA; Kremer LE; Allende L; Díaz Mdel P; Pisano MB; Contigiani MS; Ré VE
Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):432-7. PubMed ID: 23761392
[TBL] [Abstract][Full Text] [Related]
3. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
[TBL] [Abstract][Full Text] [Related]
4. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting.
Bloch M; Farris M; Tilden D; Gowers A; Cunningham N
Sex Health; 2010 Mar; 7(1):17-24. PubMed ID: 20152091
[TBL] [Abstract][Full Text] [Related]
5. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
6. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.
Sungkanuparph S; Groger RK; Overton ET; Fraser VJ; Powderly WG
HIV Med; 2006 Oct; 7(7):437-41. PubMed ID: 16925729
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
Fournier S; Chaffaut C; Maillard A; Loze B; Lascoux C; Gérard L; Timsit J; David F; Bergmann JF; Oksenhendler E; Sereni D; Chevret S; Molina JM
HIV Med; 2005 Mar; 6(2):129-34. PubMed ID: 15807719
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
9. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection.
Kaufmann GR; Khanna N; Weber R; Perrin L; Furrer H; Cavassini M; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Antivir Ther; 2004 Apr; 9(2):263-74. PubMed ID: 15134189
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.
Miller CD; El-Kholi R; Faragon JJ; Lodise TP
Pharmacotherapy; 2007 Oct; 27(10):1379-86. PubMed ID: 17896893
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
13. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
14. Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort).
Marcellin F; Lions C; Winnock M; Salmon D; Durant J; Spire B; Mora M; Loko MA; Dabis F; Dominguez S; Roux P; Carrieri MP;
Addiction; 2013 Jul; 108(7):1250-8. PubMed ID: 23421419
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
[TBL] [Abstract][Full Text] [Related]
16. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.
Trotta MP; Cozzi-Lepri A; Ammassari A; Vecchiet J; Cassola G; Caramello P; Vullo V; Soscia F; Chiodera A; Ladisa N; Abeli C; Cauda R; Buonuomi AR; Antinori A; d'Arminio Monforte A;
Clin Infect Dis; 2010 Aug; 51(4):456-64. PubMed ID: 20597690
[TBL] [Abstract][Full Text] [Related]
17. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand.
Chaiwarith R; Wachirakaphan C; Kotarathititum W; Praparatanaphan J; Sirisanthana T; Supparatpinyo K
Int J Infect Dis; 2007 Sep; 11(5):413-6. PubMed ID: 17331776
[TBL] [Abstract][Full Text] [Related]
19. Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy.
Szadkowski L; Tseng A; Walmsley SL; Salit I; Raboud JM
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1579-83. PubMed ID: 22734840
[TBL] [Abstract][Full Text] [Related]
20. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]